CA2225682A1 - Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires - Google Patents

Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires Download PDF

Info

Publication number
CA2225682A1
CA2225682A1 CA002225682A CA2225682A CA2225682A1 CA 2225682 A1 CA2225682 A1 CA 2225682A1 CA 002225682 A CA002225682 A CA 002225682A CA 2225682 A CA2225682 A CA 2225682A CA 2225682 A1 CA2225682 A1 CA 2225682A1
Authority
CA
Canada
Prior art keywords
cells
agent
cell
tci
dthd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002225682A
Other languages
English (en)
Inventor
Philip M. Grimley
Sunil Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2225682A1 publication Critical patent/CA2225682A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention se rapporte à un procédé amélioré destiné à induire des lésions cellulaires, par l'administration d'un agent de ralentissement (RA) à une population cellulaire cible en une concentration suffisante et dans des conditions appropriées pour retarder, mais non interrompre la progression des cellules cibles dans le cycle cellulaire, et l'administration simultanée ou ultérieure à celle de l'agent de ralentissement, d'un agent d'agression cytotoxique ciblé (TCI). L'invention se rapporte également à un système indicateur en microculture et à des procédures d'analyse de données auxiliaires visant à identifier, concevoir et utiliser de nouveaux agents comme agents de ralentissement ou agents d'agression cytotoxiques ciblés, ainsi qu'à améliorer les associations synergiques des agents existants. Dans des modes de réalisation de l'invention, l'agent de ralentissement peut être un inhibiteur de ribonucléotide réductase, de dihydrofolate réductase, de thymidylate synthase, d'ADN polymérase, de protéine kinase ou de topoisomérase. En outre, selon des variantes de l'invention on utilise, comme agent TCI, les indole carbazoles tels que la staurosporine, K252a, KT5926, et KT5720. Dans une variante spécifique, l'agent de ralentissement est la thymidine et l'agent TCI est la staurosporine.
CA002225682A 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires Abandoned CA2225682A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54695P 1995-06-27 1995-06-27
US60/000,546 1995-06-27
US66893296A 1996-06-24 1996-06-24
US08/668,932 1996-06-24
PCT/US1996/010921 WO1997001344A2 (fr) 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires

Publications (1)

Publication Number Publication Date
CA2225682A1 true CA2225682A1 (fr) 1997-01-16

Family

ID=26667798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002225682A Abandoned CA2225682A1 (fr) 1995-06-27 1996-06-26 Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires

Country Status (5)

Country Link
EP (1) EP0835111A2 (fr)
JP (1) JPH11509193A (fr)
AU (1) AU715527B2 (fr)
CA (1) CA2225682A1 (fr)
WO (1) WO1997001344A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143332A1 (en) * 2006-11-17 2010-06-10 Schering Corporation Combination therapy for proliferative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448534A (en) * 1978-03-30 1984-05-15 American Hospital Corporation Antibiotic susceptibility testing
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
WO1992019765A1 (fr) * 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
PT100424A (pt) * 1991-07-03 1993-10-29 Regeneron Pharma Processo e sistema de ensaio para a actividade da neurotrofina
DE69233169T2 (de) * 1991-11-15 2004-05-27 Smithkline Beecham Corp. Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
CA2140653A1 (fr) * 1992-08-12 1994-03-03 Irene Abraham Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
JPH08511785A (ja) * 1993-06-17 1996-12-10 チバ−ガイギー アクチェンゲゼルシャフト プロテインキナーゼｃ阻害剤として有用なインドロカルバゾール

Also Published As

Publication number Publication date
EP0835111A2 (fr) 1998-04-15
AU6396096A (en) 1997-01-30
JPH11509193A (ja) 1999-08-17
AU715527B2 (en) 2000-02-03
WO1997001344A3 (fr) 1997-03-27
WO1997001344A2 (fr) 1997-01-16

Similar Documents

Publication Publication Date Title
Zabludoff et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Ferreira et al. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective
Balaña-Fouce et al. Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis
Hoshikawa et al. Enhancement of the radiation effects by D-allose in head and neck cancer cells
Sauter et al. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells
CA2976537C (fr) Compositions et methodes pour le traitement de degradations de la retine
Shi et al. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines
Hu et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
US20200040100A1 (en) Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
Zhu et al. Activating transcription factor 4 mediates a multidrug resistance phenotype of esophageal squamous cell carcinoma cells through transactivation of STAT3 expression
US6274576B1 (en) Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
JP6391561B2 (ja) がんの予防または治療用医薬組成物
KR20140014086A (ko) 파클리탁셀과 cdk 억제제의 약제학적 조합물
Tai et al. Chemovirotherapeutic treatment using camptothecin enhances oncolytic measles virus-mediated killing of breast cancer cells
An et al. PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth
Vishnoi et al. Berberine represses β-catenin translation involving 4E-BPs in hepatocellular carcinoma cells
Chernyshev Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs
Delaney et al. A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer
US8623854B2 (en) Nuclear export inhibitors of topoisomerase II alpha
CN104324035A (zh) 一种自噬抑制剂与拉帕替尼组合物及其用途
CA2225682A1 (fr) Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires
Catley et al. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly (ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
Yin et al. Actinomycin D-activated RNase L promotes H2A. X/H2B-mediated DNA damage and apoptosis in lung cancer cells
Hu et al. Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation
Krishna et al. Cytotoxic studies of anti-neoplastic drugs on human lymphocytes–In vitro studies

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040628